Summit Therapeutics Inc. (SMMT)
Automate Your Wheel Strategy on SMMT
With Tiblio's Option Bot, you can configure your own wheel strategy including SMMT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SMMT
- Rev/Share 0.0
- Book/Share 0.2586
- PB 64.0319
- Debt/Equity 0.0282
- CurrentRatio 3.796
- ROIC -4.6868
- MktCap 12327968429.0
- FreeCF/Share -0.366
- PFCF -45.3048
- PE -13.358
- Debt/Assets 0.0207
- DivYield 0
- ROE -3.1115
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SMMT | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 18, 2025 |
| Initiation | SMMT | Barclays | -- | Underweight | -- | $13 | Sept. 17, 2025 |
| Initiation | SMMT | Guggenheim | -- | Buy | -- | $40 | Sept. 4, 2025 |
| Initiation | SMMT | Piper Sandler | -- | Neutral | -- | $21 | Aug. 19, 2025 |
| Initiation | SMMT | UBS | -- | Buy | -- | $30 | July 1, 2025 |
| Initiation | SMMT | Leerink Partners | -- | Underperform | -- | $12 | June 11, 2025 |
| Upgrade | SMMT | Citigroup | Neutral | Buy | $23 | $35 | March 26, 2025 |
| Initiation | SMMT | Cantor Fitzgerald | -- | Overweight | -- | -- | March 21, 2025 |
| Initiation | SMMT | Evercore ISI | -- | Outperform | -- | $30 | March 12, 2025 |
| Initiation | SMMT | Goldman | -- | Buy | -- | $42 | Feb. 28, 2025 |
News
Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Summit Therapeutics Inc. ( SMMT ) Jefferies London Healthcare Conference 2025 November 18, 2025 10:30 AM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Clara Dong Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good afternoon.
Read More
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
Published: November 07, 2025 by: Business Wire
Sentiment: Neutral
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, conducted in China and sponsored by Akeso, featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, M.
Read More
Insiders Are Buying These 3 Stocks Hand Over Fist
Published: October 28, 2025 by: 24/7 Wall Street
Sentiment: Positive
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.
Read More
Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Negative
Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically significant overall survival data. SMMT faces heightened financing risk due to increased trial enrollment and a limited cash runway, with dilution likely if partnerships don't materialize soon. The company's bold BLA strategy and expanded Phase 3 footprint increase binary risk, while regulatory and commercial uncertainties persist without clear OS benefit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT).
Read More
Ten Bull Market 10-Baggers
Published: September 22, 2025 by: Seeking Alpha
Sentiment: Positive
While broad market performance has been robust, one striking aspect of this cycle has been the extraordinary gains in a handful of individual equities. Ten stocks in the large-cap Russell 1,000 have now advanced more than 1,000% since the start of this period. We take a look at each of these names to provide insight into the breadth of forces powering this bull market beyond the headline indices.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: September 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Summit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
Read More
Top 3 Health Care Stocks You'll Regret Missing In Q3
Published: September 09, 2025 by: Benzinga
Sentiment: Positive
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Read More
Summit Therapeutics (SMMT) WCLC Update Call (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Summit Therapeutics (NASDAQ:SMMT ) WCLC Update Conference Call September 08, 2025 08:00 AM Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West - Vice President of Clinical Development Manmeet Soni - COO, CFO & Director Urte Gayko - Chief Regulatory, Quality & Pharmacovigilance Officer Robert Duggan - Co-CEO & Executive Chairman Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Mohit …
Read More
Summit Therapeutics shares fall as lung cancer trial results disappoint
Published: September 08, 2025 by: Proactive Investors
Sentiment: Negative
Summit Therapeutics PLC (NASDAQ:SMMT) shares dropped sharply on Monday following the release of mixed results from its Phase III HARMONi trial of ivonescimab, a potential lung cancer therapy. The stock fell 23.4% to about $20 in the early afternoon.
Read More
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Read More
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
Read More
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Read More
2 Soaring Stocks With More Upside Potential to Buy and Hold
Published: July 04, 2025 by: The Motley Fool
Sentiment: Positive
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends.
Read More
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: July 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
Summit Therapeutics: Market Overreaction Creates Opportunity
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
Summit's ivonescimab showed a 48% reduction in disease progression risk in EGFR-mutant lung cancer — a best-in-class result in a tough-to-treat population. Overall survival data is trending positive but has not yet reached statistical significance; further follow-up may tip the balance. The recent stock sell-off reflects regulatory uncertainty rather than drug failure, creating a potential buying opportunity for long-term investors.
Read More
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Negative
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
Read More
About Summit Therapeutics Inc. (SMMT)
- IPO Date 2015-03-05
- Website https://www.summittxinc.com
- Industry Biotechnology
- CEO Robert W. Duggan
- Employees 159